Medicover (MCOV-B.ST) Stock Analysis & AI Equity Report

Medical - Equipment & Services SEK Explore free reports

Medicover (MCOV-B.ST) overview

Medicover (MCOV-B.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Medicover reported revenue of EUR 2,092m and operating profit of EUR 70.3m; the year-end share price was 192.00 SEK and market capitalisation was SEK 28,827m. Medicover is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Medicover's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueEUR 465mFY 2024
Share price192.00 SEKFY 2024 year end
RevenueEUR 2,092mFY 2024
Operating profitEUR 70.3mFY 2024
Net earningsEUR 14.6mFY 2024
Market capitalisationSEK 28,827mFY 2024 year end

Figures updated on 2025-09-03. Data will be refreshed during report generation.

About Medicover

Medicover AB (publ) provides healthcare services and diagnostic laboratory testing through two divisions. Healthcare Services offers outpatient and inpatient care, dentistry, fertility treatments, pharmacies, gyms and other wellbeing services, while Diagnostic Services runs laboratories, blood-drawing points and clinics that provide routine and advanced tests across major clinical areas in multiple European markets.

Generate the Medicover report

Medicover is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, typically within about 30 minutes

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Medicover and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.